New drug combo shows promise for rare nerve cancer in NF1 patients

NCT ID NCT06693284

Recruiting now Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a 28-day course of two oral drugs (mirdametinib and vorinostat) in people aged 12+ with a rare, aggressive nerve tumor linked to NF1. The goal is to see if the combination is safe and can shrink or change the tumor before standard treatment (radiation and surgery). Only 8 participants will be enrolled, and they will have biopsies and scans before and after the drug course.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant peripheral nerve sheath tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55414, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••